Stibium Metallicum Praeparatum 6x Versus Placebo in the Prevention of Paclitaxel-induced Peripheral Neurotoxicity (PROPEL NO TOX)
Subcutaneous Stibium Metallicum Praeparatum 6x Versus Placebo in the PRevention Of PaclitaxEL-induced Peripheral NeurOTOXicity: the PROPEL NO TOX Randomized Controlled Trial
Sponsor: Gesundheitszentrum Fricktal AG
A PHASE3 clinical study on Chemotherapy Induced Peripheral Neuropathy (CIPN), this trial is actively recruiting participants. The trial is conducted by Gesundheitszentrum Fricktal AG and has accumulated 10 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Not Yet Recruiting PHASE3
-
Nov 2024 — Dec 2025 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
▶ Show 5 earlier versions
-
Jul 2023 — Mar 2024 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2022 — Apr 2023 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gesundheitszentrum Fricktal AG
- Hospital of Thun
- Insel Gruppe AG, University Hospital Bern
- Kantonsspital Aarau
- Kantonsspital Graubünden
- Kantonsspital Winterthur KSW
- Tumor- und BrustZentrum Ostschweiz
- University of Bern
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.